Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Lars Bossen
  • Paola Rebora, University of Milan - Bicocca
  • ,
  • Francesca Bernuzzi, University of Milan - Bicocca
  • ,
  • Peter Jepsen
  • Alessio Gerussi, University of Milan - Bicocca, Azienda Ospedaliera San Gerardo Monza
  • ,
  • Pietro Andreone, University of Bologna
  • ,
  • Andrea Galli, University of Florence
  • ,
  • Benedetta Terziroli, Epatocentro Ticino
  • ,
  • Domenico Alvaro, University of Rome La Sapienza
  • ,
  • Giancarlo Labbadia, University of Rome La Sapienza
  • ,
  • Chiara Aloise, University of Milan - Bicocca
  • ,
  • Leonardo Baiocchi, University of Rome Tor Vergata
  • ,
  • Edoardo Giannini, University of Genoa
  • ,
  • Ludovico Abenavoli, Magna Græcia University
  • ,
  • Pierluigi Toniutto, University of Udine
  • ,
  • Fabio Marra, Epatocentro Ticino
  • ,
  • Marco Marzioni, Marche Polytechnic University
  • ,
  • Grazia Niro, IRCCS Ospedale Casa Sollievo della Sofferenza - San Giovanni Rotondo (FG)
  • ,
  • Annarosa Floreani, University of Padova
  • ,
  • Holger J. Møller
  • Maria G. Valsecchi, University of Milan - Bicocca
  • ,
  • Marco Carbone, Division of Gastroenterology, University of Milan - Bicocca, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Azienda Ospedaliera San Gerardo Monza
  • ,
  • Henning Grønbæk
  • Pietro Invernizzi, University of Milan - Bicocca, Azienda Ospedaliera San Gerardo Monza

Introduction: In primary biliary cholangitis (PBC), macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in patients with PBC. Methods: We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (a) death from a liver-related cause; or (b) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long-term prognosis. Results: In total, 202 PBC patients were included. Median age was 62 years (interquartile range (IQR), 53-71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48-5.35) and median sMR was 0.35 mg/L (IQR 0.28-0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two hundred and one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long-term risk of liver-related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR = 1.14, 95% CI 1.00-1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK-PBC risk score. Conclusion: The macrophage activation markers sCD163 and sMR represent a non-invasive measure of PBC disease severity that provides useful long-term prognostic information.

OriginalsprogEngelsk
TidsskriftLiver International
Vol/bind40
Nummer6
Sider (fra-til)1408-1414
ISSN1478-3223
DOI
StatusUdgivet - jun. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 189719565